To: Network Pharmacy  
From: Elixir  
Date: Friday, April 30th, 2021  
Re: The Pharmacy Audit Whisperer – Avoiding Audit Chargebacks  

The purpose of this communication is to share reminders and tips on: 
- Audit timeliness  
- Continued appropriate utilization of Service Code Override 13  
- Accurate claims submission  

Audit Timeliness  
- Elixir expects pharmacies to respond to audit requests within the allotted time frame as indicated on the audit request and discrepancy letters. Audit extensions are considered on a case by case basis and handled in writing only via email or fax. Extension requests received less than three (3) days prior to the due date for an audit response will not be considered. Extension requests may be approved or denied at Elixir’s discretion.  
- Pharmacies that did not respond to the audit request are voiding their right to appeal findings encountered upon record review.  
- Investigational audits, Medicare, and/or Medicaid Plan Sponsor-requested desk audits have shorter turnaround time for responses.  

Continued Use of Service Code Override 13  
Utilize SCC-13 override when the patient requests refill(s) due to the COVID-19 crisis or other payer recognized emergency situations. Do not use SCC-13 to override refill too soon rejections unless related to the state of emergency. Lack of proper documentation, abusive, or careless use of SCC-13 is subject to audit and charge backs. Ensure your pharmacy claims adjudication software does not carry over the SCC-13 across refills to avoid audit scrutiny.  

Accurate Claims Submission  
The following tips and reminders are based on recent discrepancies found during audit and claims review:  
- Topical Medications  
  o Require directions that reflect a treatment area and/or calculable amount to derive the accurate days’ supply. During an audit, directions that state UAD for 30 days will not be accepted for more than the smallest package size available.  
  o When utilizing online calculators to determine dispense quantity for topical products, keep in mind that the calculator can round up the quantity needed based on meeting the minimum days’ supply entered. Measurements are required to be documented on the prescription hard copy when the manufacturer calculators are available.  
- Ophthalmic Medications  
  o Use the calculation per Elixir Pharmacy Manual unless the manufacturer provides a specified calculation in the drug insert.  
  o Be mindful of unique expirations once the bottle is opened. For example, Rhopressa and Latanoprost expire six weeks after opening.  
- Initiated Prescriptions: Pharmacy shall not deliver Covered Drugs to a Member without the Member’s consent prior to each delivery. Additionally, Pharmacy agrees that it will not bill for reimbursement for Member’s Covered Drug prescriptions until and unless the Member has received such prescriptions.
• Pharmacies must be aware of Medicare Part D requirements when submitting claims for Part D beneficiaries. Covered Part D drugs are prescribed for “medically-accepted indications” i.e. use of medication according to FDA approved labeling or off label use if drugs are identified as safe and effective for use in one of the officially recognized drug compendia. Payments for Part D drugs that are not for medically accepted indications are considered potential fraud or abuse.

• Pharmacies should be familiar with practices that may constitute a breach of the Participating Provider Agreement as listed on page 10-11 of the Elixir Pharmacy Manual. The current version can be found here: https://www.elixirsolutions.com/content/dam/elixirdotcom/providers/Pharmacy%20Manual%20v47.pdf

All Pharmacy Audit Whisperer communications are available at Elixir’s website, under the “Providers” > “Pharmacy Resources” > “Bulletins and Communications” section, at https://www.elixirsolutions.com/providers. Please make sure to consult all past communications to remain in compliance with network expectations.

If you have any questions regarding this communication, please contact PharmacyAudits@elixirsolutions.com.

Thank you,

Elixir